<DOC>
	<DOCNO>NCT01441635</DOCNO>
	<brief_summary>The purpose proof-of-concept study determine whether elagolix ( ABT-620 ) safe effective treatment pre-menopausal woman , 20 49 year age , heavy uterine bleeding associate uterine fibroid . The effect elagolix ( ABT-620 ) uterine size , fibroid size , bleed associate uterine fibroid assess versus placebo , combination add-back therapy .</brief_summary>
	<brief_title>Safety Efficacy Pre-Menopausal Women With Heavy Uterine Bleeding Uterine Fibroids</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Subject premenopausal female â‰¥ 20 year age . Subject diagnosis uterine fibroid document Pelvic Ultrasound . Subject history regular menstrual cycle 24 35 day . Subject heavy uterine bleeding associate uterine fibroid . Subject myomectomy , uterine artery embolization , endometrial ablation high intensity focus ultrasound fibroid destruction within 1 year prior randomization history endometrial ablation . Subject history osteoporosis metabolic bone disease . Subject show evidence clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric ( include depression ) , neurologic disease uncontrolled medical illness uncontrolled type 2 diabetes . Subject history clinically significant condition ( ) include limited : Endometriosis Epilepsy seizures Type 1 diabetes Any cancer ( except basal cell carcinoma skin ) , include breast ovarian cancer subject take systemic cancer chemotherapy</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Elagolix</keyword>
	<keyword>Uterine Fibroids</keyword>
	<keyword>Elagolix sodium</keyword>
	<keyword>Leiomyomata</keyword>
	<keyword>Heavy Uterine Bleeding</keyword>
	<keyword>Menorrhagia</keyword>
	<keyword>ABT-620</keyword>
</DOC>